Posters

Objective quality of vision and visual acuity with a new hydrophobic asymmetric–refractive extended-depth-of-focus (EDOF) IOL

Poster Details

First Author: C.Herbers GERMANY

Co Author(s):    I. Kaiser   R. Lucchesi   J. Winters   M. Moftah   S. Abdassalam   F. Kretz     

Abstract Details

Purpose:

To evaluate the objective quality of vision as well as the visual acuity for different distances after implantation of a new hydrophobic asymmetric-refractive extended depth of focus (EDOF) IOL.

Setting:

All implantations and follow-ups were performed at the AUGENKLINIK in Rheine and Greven, Germany

Methods:

This prospective analysis comprises results after binocular implantation of the new asymmetric-refractive EDOF IOL Acunex Vario (Teleon Surgical B.V.) in 40 eyes. Follow up exams were performed at one month after surgery. Results for manifest refraction (ETDRS), uncorrected and corrected visual acuity for distance, intermediate at 90 cm,80 cm and 60 cm as well as for near at 40cm. The objective quality of vision was evaluated with the HD Analyser. Point spread function (PSF), Modulation transfer function (MTF) and Objective scatter index (OSI) were documented.

Results:

Visual acuity increased for all distances with UDVA 0.05 (SD+/-0.07) logMAR, UIVA 0.09 (SD+/-0.07) logMAR for 90cm, UIVA 0.12 (SD+/-0.08) logMAR for 80cm and UIVA 0.21 (SD+/-0.11) logMAR for 60cm. UNVA was documented with 0.26 (SD+/-0.12) logMAR. All eyes were within +/-1.0 D deviation from target SE. PSF, MTF und OSI values were similar to monofocal IOLs.

Conclusions:

The EDOF IOL Acunex Vario provides a very good predictability and patients can benefit from a very good vision from distance up to 60 cm intermediate with no compromises in objective quality of vision.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a competing company, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented